The International Journal of Cardiology published a prospective cohort study online on 8 September 2026 by Karanxha, Guni, Xhabija, Dede, Mone and Prifti, from American Hospital and the University of Medicine in Tirana, with a co-author at Sorbonne Université in Paris.

Fifty adults with obesity-related heart failure with preserved ejection fraction started tirzepatide in routine care and were followed for a median of 5.8 months. Every measurement the study recorded moved in the same direction.

That is the result and also the reason to read it carefully.

A framing note. This is an approved medicine studied in clinical practice. Peptra Labs supplies Tirzepatide as a reference material for laboratory research only, and nothing below is guidance about human use or about any medical condition.

What the tirzepatide cohort measured

The design is stated plainly. A prospective, single-centre, longitudinal observational cohort of 50 adults with an ejection fraction of 50 percent or above and a body mass index of 30 or above, all of them starting the drug in routine care rather than under a trial protocol.

The co-primary endpoints were the change in left ventricular mass and the change in the E over e prime ratio, from baseline to approximately six months. Both are echocardiographic measures, the first of how much muscle the left ventricle has laid down and the second an estimate of filling pressure.

Multiplicity was controlled by hierarchical gate-keeping with a Benjamini-Hochberg false discovery rate correction, which is why the results are reported as q values rather than p values.

The tirzepatide numbers

Left ventricular mass fell by 12.4 g, with a 95 percent confidence interval from minus 15.4 to minus 9.4, and a standardised response mean of minus 1.16.

The E over e prime ratio improved by 1.45, confidence interval minus 1.85 to minus 1.11, standardised response mean minus 1.08.

Beyond the co-primary endpoints, the Kansas City Cardiomyopathy Questionnaire score rose by 13.1 points, six-minute walk distance by 43 m, and body mass index fell by 5.8. NT-proBNP, high-sensitivity C-reactive protein and high-sensitivity troponin T all declined significantly. New York Heart Association class improved in 30 patients, 60 percent of the cohort, with none worsening.

Those two standardised response means are large. A value above one means the change was bigger than the variability of the change, which is a strong signal in a cohort of this size.

The part the tirzepatide cohort cannot answer

There is no control arm. That single fact governs how far every number above can travel.

Over 5.8 months these participants lost 5.8 units of body mass index, which, depending on height, works out at roughly 15 to 18 kg, a figure the paper does not report directly. Reverse remodelling of the left ventricle is an expected consequence of substantial weight loss on its own. Nothing in this design separates the effect of the drug from the effect of the weight, from changes to the rest of the medication regimen, or from regression to the mean in people enrolled while they were unwell enough to start something new.

Two of the secondary measures are also the kind that move on their own in an unblinded study. A symptom questionnaire and a walking test both depend on what the participant knows and how hard they try, and everyone here knew they had started a new treatment.

The echocardiographic endpoints are more robust to that, though reading an echocardiogram is not fully operator-independent either, and the abstract does not say whether the readers were blinded to the time point.

What the authors do and do not claim

The conclusion is worded with more care than the numbers alone would require, and the wording is worth noticing.

They write that tirzepatide use was associated with reverse cardiac remodelling, improved diastolic function and better health status. Associated, not caused. They then say the findings complement randomised trial evidence and support further evaluation, which is the correct request from an uncontrolled cohort.

The multiplicity control is the detail that separates this paper from most real-world series. Eight or more outcomes were tested and the false discovery rate was corrected for, in a hierarchical order set in advance. A study willing to do that is a study aware that testing many things at once produces significant results by itself.

The authors declare no competing interests.

Where the tirzepatide cohort sits against the rest

We covered a matched database cohort in the same condition read by sex in August, built from a federated database of 110 healthcare organisations and 3,308 matched patients. That study had the numbers this one lacks and no echocardiographic endpoints at all. This one has 50 patients and two structural measurements taken directly.

Neither is randomised, and neither can establish that tirzepatide caused what was observed. The randomised trial evidence the authors say their findings complement is not something we have covered, and these two articles read together are not a substitute for it.

What a single-centre cohort of 50 people in Tirana adds is narrower than that. It is a different health system, a different population and routine care rather than protocol care, and the direction of effect held.

That is a modest and real contribution. It is not evidence of a magnitude, and the 12.4 g figure should not be quoted as one.

Reading it alongside the rest of the week

The wider record on this class is more mixed than a single cohort suggests, which is exactly why the caveats matter.

We covered a narrative review that listed cardiovascular benefit among several summarised gains, and separately the cardiovascular outcome trial behind its approval, which met non-inferiority and missed superiority. We also covered a comparison in resistant hypertension where blood pressure fell no further than with the guideline comparator.

A cohort where everything improves and a trial where the primary endpoint narrowly does not are both true statements about the same drug. The difference between them is the control arm.

What it means for the laboratory

The transferable point is about endpoint choice rather than cardiology.

Left ventricular mass and E over e prime are structural measurements with defined units, and they moved with effect sizes above one. Symptom scores and walk tests moved too, and carry far less information in an unblinded setting. Any study design faces the same trade, and the endpoints that survive the absence of blinding are the ones worth building around.

Retatrutide adds a third receptor to the same pharmacology and has no cohort like this behind it yet, which is the ordinary situation for a compound still in trials.

For laboratories, our European research buyer guide covers procurement and documentation, and everything is supplied on a research use only basis.

References

The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.

author-avatar

About Peptra Labs Research

The Peptra Labs research desk follows peptide science: new peer-reviewed studies, EU and US regulatory decisions, and clinical trial results. Every article cites its primary sources. All compounds discussed are for laboratory research use only.

Newer
Nanocarriers of 4 to 30 nm Cut Fat, Not Food Intake
Back to list
Older Tirzepatide 15 mg: 1.60 kg of Fat-Free Mass Lost

Related Posts